欧林生物
(688319)
| 流通市值：114.33亿 | | | 总市值：114.33亿 |
| 流通股本：4.05亿 | | | 总股本：4.05亿 |
| 报告期 | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 598,935,631.15 | 361,322,181.04 | 157,803,808.92 | 704,160,325.32 |
| 营业收入 | 598,935,631.15 | 361,322,181.04 | 157,803,808.92 | 704,160,325.32 |
| 二、营业总成本 | 506,294,647.39 | 310,823,899.43 | 136,476,818.31 | 659,117,720.56 |
| 营业成本 | 46,717,459.4 | 29,581,641.24 | 12,874,679.08 | 49,579,783.45 |
| 税金及附加 | 7,772,188.23 | 6,170,158.82 | 2,609,283.33 | 6,052,593.97 |
| 销售费用 | 316,911,136.15 | 181,599,336.42 | 76,872,019.28 | 380,936,224.6 |
| 管理费用 | 52,252,547.14 | 35,278,519.05 | 19,719,862.19 | 75,161,385.81 |
| 研发费用 | 69,776,584.46 | 49,679,737.58 | 20,187,151.24 | 132,904,807.21 |
| 财务费用 | 12,864,732.01 | 8,514,506.32 | 4,213,823.19 | 14,482,925.52 |
| 其中:利息费用 | 13,033,996.61 | 8,442,519.63 | 4,120,209.37 | 14,644,287.81 |
| 其中:利息收入 | 273,121.62 | 177,997.22 | 79,925.01 | 603,556.94 |
| 三、其他经营收益 | | | | |
| 加:投资收益 | 125,136.99 | 125,136.99 | 125,136.99 | 497,841.77 |
| 资产处置收益 | -396,119.37 | - | - | 8,707.5 |
| 资产减值损失(新) | 521,237.93 | 4,024,665.1 | 5,635,839.5 | -13,585,517.39 |
| 信用减值损失(新) | -16,076,773.01 | -6,431,470.69 | 1,294,328.2 | -13,033,370.76 |
| 其他收益 | 9,351,108.14 | 8,876,541.53 | 4,010,106.65 | 11,926,905.6 |
| 四、营业利润 | 86,165,574.44 | 57,093,154.54 | 32,392,401.95 | 30,857,171.48 |
| 加:营业外收入 | 5,071.65 | 33,328.37 | 29,983.47 | 1,191,401.4 |
| 减:营业外支出 | 32,045,633.09 | 30,942,072.97 | - | 155,362.99 |
| 五、利润总额 | 54,125,013 | 26,184,409.94 | 32,422,385.42 | 31,893,209.89 |
| 减:所得税费用 | 60,933,788.94 | 59,064,100.86 | 5,224,670.74 | 9,994,472.7 |
| 六、净利润 | -6,808,775.94 | -32,879,690.92 | 27,197,714.68 | 21,898,737.19 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | -6,808,775.94 | - | 27,197,714.68 | 21,898,737.19 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | -6,801,641.54 | -32,872,556.52 | 27,189,316.87 | 22,260,140.53 |
| 少数股东损益 | -7,134.4 | -7,134.4 | 8,397.81 | -361,403.34 |
| 扣除非经常损益后的净利润 | 16,873,591.6 | -10,062,036.14 | 23,278,017.1 | 9,907,937.75 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | -0.02 | -0.08 | 0.07 | 0.05 |
| (二)稀释每股收益 | -0.02 | -0.08 | 0.07 | 0.05 |
| 九、综合收益总额 | -6,808,775.94 | - | 27,197,714.68 | 21,898,737.19 |
| 归属于母公司股东的综合收益总额 | -6,801,641.54 | - | 27,189,316.87 | 22,260,140.53 |
| 归属于少数股东的综合收益总额 | -7,134.4 | - | 8,397.81 | -361,403.34 |
| 公告日期 | 2026-10-30 | 2026-08-18 | 2026-04-30 | 2026-03-31 |
| 审计意见(境内) | | | | 标准无保留意见 |